US FDA grants Orphan Drug Designation to BlueRock Therapeutics’ investigational cell therapy OpCT-001 to treat retinitis pigmentosa: Berlin, Germany Friday, January 23, 2026, 09 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback